Primary |
Drug Use For Unknown Indication |
35.7% |
Urinary Tract Infection |
23.1% |
Cystitis |
5.4% |
Infection |
3.8% |
Prostatitis |
3.8% |
Diverticulitis |
3.4% |
Product Used For Unknown Indication |
3.4% |
Hypertension |
3.1% |
Sinusitis |
2.7% |
Prophylaxis |
2.1% |
Prostate Infection |
2.0% |
Kidney Infection |
1.7% |
Pneumonia |
1.7% |
Pain |
1.6% |
Infection Prophylaxis |
1.4% |
Unevaluable Event |
1.4% |
Ear Infection |
1.2% |
Bronchitis |
1.1% |
Cellulitis |
1.0% |
Crohn's Disease |
0.8% |
|
Tendon Rupture |
12.6% |
Tendonitis |
12.6% |
Tendon Pain |
7.1% |
Drug Hypersensitivity |
6.7% |
Rash |
6.1% |
Pain In Extremity |
6.0% |
Vomiting |
5.4% |
No Adverse Event |
5.0% |
Tendon Disorder |
4.7% |
Urticaria |
4.2% |
Pruritus |
3.9% |
Tinnitus |
3.5% |
Tremor |
3.5% |
Weight Decreased |
3.5% |
Urinary Tract Infection |
3.4% |
Paraesthesia |
2.9% |
Arthralgia |
2.6% |
Nausea |
2.2% |
Adverse Event |
2.1% |
Neuropathy Peripheral |
2.1% |
|
Secondary |
Drug Use For Unknown Indication |
18.0% |
Product Used For Unknown Indication |
16.4% |
Urinary Tract Infection |
11.7% |
Hypertension |
7.6% |
Infection |
5.3% |
Pain |
4.8% |
Prophylaxis |
4.5% |
Infection Prophylaxis |
3.6% |
Diverticulitis |
3.5% |
Pneumonia |
3.0% |
Sinusitis |
2.8% |
Prostatitis |
2.7% |
Osteoarthritis |
2.5% |
Bronchitis |
2.4% |
Rheumatoid Arthritis |
2.4% |
Cystitis |
2.1% |
Parenteral Nutrition |
1.8% |
Prophylaxis Against Gastrointestinal Ulcer |
1.8% |
Thrombosis Prophylaxis |
1.8% |
Diabetes Mellitus |
1.7% |
|
Drug Hypersensitivity |
19.2% |
Tendonitis |
12.2% |
Tendon Rupture |
11.7% |
Vomiting |
10.9% |
Urinary Tract Infection |
8.0% |
Weight Decreased |
5.6% |
Toxic Epidermal Necrolysis |
5.4% |
Renal Failure Acute |
3.4% |
Death |
2.7% |
Stevens-johnson Syndrome |
2.4% |
Diarrhoea |
2.2% |
Pain In Extremity |
2.2% |
Clostridial Infection |
1.9% |
Liver Injury |
1.9% |
Paraesthesia |
1.7% |
Rash |
1.7% |
Retching |
1.7% |
Urticaria |
1.7% |
Weight Increased |
1.7% |
White Blood Cell Count Increased |
1.7% |
|
Concomitant |
Product Used For Unknown Indication |
29.1% |
Drug Use For Unknown Indication |
22.1% |
Crohn's Disease |
11.9% |
Pain |
5.6% |
Hypertension |
3.9% |
Prophylaxis |
3.0% |
Multiple Myeloma |
2.7% |
Depression |
2.4% |
Rheumatoid Arthritis |
1.9% |
Breast Cancer |
1.9% |
Urinary Tract Infection |
1.8% |
Contraception |
1.8% |
Anxiety |
1.7% |
Nausea |
1.7% |
Gastrooesophageal Reflux Disease |
1.6% |
Acne |
1.5% |
Osteoporosis |
1.4% |
Asthma |
1.4% |
Premedication |
1.3% |
Non-small Cell Lung Cancer |
1.2% |
|
Weight Decreased |
15.2% |
Vomiting |
14.1% |
Urinary Tract Infection |
12.0% |
Weight Increased |
6.7% |
Pyrexia |
5.9% |
Pulmonary Embolism |
5.2% |
White Blood Cell Count Decreased |
4.9% |
Pneumonia |
3.9% |
Thrombocytopenia |
3.7% |
Pain |
3.6% |
Renal Failure Acute |
3.2% |
Crohn's Disease |
2.9% |
White Blood Cell Count Increased |
2.8% |
Nausea |
2.6% |
Death |
2.5% |
Sepsis |
2.4% |
Viral Infection |
2.4% |
Vision Blurred |
2.1% |
Drug Ineffective |
2.0% |
Type 2 Diabetes Mellitus |
2.0% |
|
Interacting |
Hypertension |
14.7% |
Product Used For Unknown Indication |
11.8% |
Prostatitis |
11.8% |
Urinary Tract Infection |
7.8% |
Drug Use For Unknown Indication |
6.9% |
Anaesthesia |
5.9% |
Gastrooesophageal Reflux Disease |
4.9% |
Angina Pectoris |
3.9% |
Pneumonia Aspiration |
3.9% |
Restless Legs Syndrome |
3.9% |
Abdominal Pain Upper |
2.9% |
Infection |
2.9% |
Pain |
2.9% |
Procedural Pain |
2.9% |
Type 2 Diabetes Mellitus |
2.9% |
Antibiotic Therapy |
2.0% |
Cardiac Failure |
2.0% |
Chronic Obstructive Pulmonary Disease |
2.0% |
Coronary Artery Disease |
2.0% |
Diabetes Mellitus |
2.0% |
|
Drug Interaction |
22.6% |
Renal Pain |
9.7% |
Urinary Tract Infection |
9.7% |
Hypoglycaemia |
6.5% |
Hypokalaemia |
6.5% |
Renal Failure Acute |
6.5% |
Arthralgia |
3.2% |
Electrocardiogram Qt Prolonged |
3.2% |
Fall |
3.2% |
Kidney Infection |
3.2% |
Micturition Disorder |
3.2% |
Nausea |
3.2% |
Renal Impairment |
3.2% |
Sepsis |
3.2% |
Serotonin Syndrome |
3.2% |
Somnambulism |
3.2% |
Sudden Death |
3.2% |
Syncope |
3.2% |
|